

Antimicrobial Stewardship

Jeanne Brady PharmD
Mahendra Poudel, MD
April 2020

Antimicrobial Stewardship

- Studies have estimated that **30-50% of antibiotics prescribed in acute-care hospitals are unnecessary or inappropriate**¹
- **Antimicrobial stewardship definition:** Coordinated interventions designed to improve and measure the appropriate use of antimicrobial agents by promoting the selection of the optimal antimicrobial drug regimen including dosing, duration of therapy, and route of administration²
- **Objectives of stewardship:** Achieving the best clinical outcomes related to antimicrobial use while minimizing toxicity and other adverse events, thereby limiting the selective pressures that drive the emergence of antimicrobial-resistant strains of bacteria

1. National Quality Forum. Antimicrobial Stewardship in Acute Care: A Practical Playbook. Accessed 10 June 2016.

2. Infectious Diseases Society of America. http://www.idsociety.org/Stewardship_Policy/. Accessed 27 March 2017.

Antibiotic Resistance: A Growing Crisis

The Threat of Antibiotic Resistance in the United States

Antibiotic resistance—when germs (bacteria, fungi) develop the ability to defeat the antibiotics designed to kill them—is one of the greatest global health challenges of modern time.

New National Estimate*

Each year, antibiotic-resistant bacteria and fungi cause at least an estimated:



2,868,700
infections



35,900 deaths



*Clostridioides difficile*** is related to antibiotic use and antibiotic resistance:



223,900
cases



12,800 deaths

New Antibiotic Resistance Threats List

Updated urgent, serious, and concerning threats—totaling 18

5 urgent threats

2 new threats

NEW: Watch List with **3** threats



Antibiotic resistance remains a significant One Health problem, affecting humans, animals, and the environment. Data show infection prevention and control is saving lives—especially in hospitals—but threats may undermine this progress without continued aggressive action now.

Learn more: www.cdc.gov/DrugResistance/Biggest-Threats.html

CDC. Antibiotic Resistance Threats in the United States, 2019
<https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf>

CDC's 2019 AR Threats Report: PREVENTION WORKS.

↓ **18%** fewer deaths from antibiotic resistance overall since 2013 report

↓ **28%** fewer deaths from antibiotic resistance in hospitals since 2013 report

AND DECREASES IN INFECTIONS CAUSED BY:

↓ **41%** Vancomycin-resistant *Enterococcus*

↓ **33%** Carbapenem-resistant *Acinetobacter*

↓ **29%** Multidrug-resistant *Pseudomonas aeruginosa*

↓ **25%** Drug-resistant *Candida*

↓ **21%** Methicillin-resistant *Staphylococcus aureus* (MRSA)

STABLE Carbapenem-resistant Enterobacteriaceae (CRE) & drug-resistant tuberculosis (TB disease cases)

CDC strategies that work in healthcare:



Preventing device- and procedure-related infections, such as from urinary catheters or central lines



Stopping the spread of resistant germs within and between healthcare facilities



Containing emerging threats through early detection and aggressive response



Tracking and improving appropriate antibiotic use



Infection prevention and control in non-hospital settings, such as long-term care facilities

CDC strategies that work in communities:



Widespread use of vaccines to prevent infections and spread



Routine tuberculosis and gonorrhea screening for at-risk groups and prompt treatment



Using safer sex practices (e.g., condoms)




Safe food handling and preparation




Improving antibiotic use everywhere


Superbugs



- Antibiotic resistance is outpacing new antibiotic development



Source: Centers for Disease Control and Prevention



Source: Infectious Diseases Society of America

CDC: Four Core Actions

Four Core Actions to Fight Resistance

1 PREVENTING INFECTIONS, PREVENTING THE SPREAD OF RESISTANCE



Avoiding infections in the first place reduces the amount of antibiotics that have to be used and reduces the likelihood that resistance will develop during therapy. There are many ways that drug-resistant infections can be prevented: immunization, safe food preparation, handwashing, and using antibiotics as directed and only when necessary. In addition, preventing infections also prevents the spread of resistant bacteria.

2 TRACKING



CDC gathers data on antibiotic-resistant infections, causes of infections and whether there are particular reasons (risk factors) that caused some people to get a resistant infection. With that information, experts can develop specific strategies to prevent those infections and prevent the resistant bacteria from spreading.

3 IMPROVING ANTIBIOTIC PRESCRIBING/STEWARDSHIP



Perhaps the single most important action needed to greatly slow down the development and spread of antibiotic-resistant infections is to change the way antibiotics are used. Up to half of antibiotic use in humans and much of antibiotic use in animals is unnecessary and inappropriate and makes everyone less safe. Stopping even some of the inappropriate and unnecessary use of antibiotics in people and animals would help greatly in slowing down the spread of resistant bacteria. This commitment to always use antibiotics appropriately and safely—only when they are needed to treat disease, and to choose the right antibiotics and to administer them in the right way in every case—is known as antibiotic stewardship.

4 DEVELOPING NEW DRUGS AND DIAGNOSTIC TESTS



Because antibiotic resistance occurs as part of a natural process in which bacteria evolve, it can be slowed but not stopped. Therefore, we will always need new antibiotics to keep up with resistant bacteria as well as new diagnostic tests to track the development of resistance.

The critical role of the staff nurse

- Antibiotic first responders
- Central communicators for the multidisciplinary care team
- Coordinators of patient care
- 24-hour monitors of patient status, safety, and response to antibiotic therapy

Nursing Interventions

- Ensure that cultures are drawn **before** antibiotics are started so that there's guidance for effective antibiotic therapy
- **Timely administration** of first-dose antibiotics.
- Patient monitoring
 - Patient response to antibiotics
 - Laboratory results
 - Microbiology culture and sensitivity reports
 - Adverse effects
- Being a patient advocate for appropriate antibiotic use
 - Ensuring good hand hygiene and isolation practices to decrease risks of infection and the spread of infections
 - If no signs of infection, ask providers/pharmacists if antibiotics are really needed and if they can be stopped
 - Asking if antibiotics can be tailored based on culture and sensitivity results
 - Advocating for IV to PO conversions



Antimicrobial Stewardship at Salinas Valley Memorial Healthcare

- SVMH has developed a multi-disciplinary, evidence-based stewardship program
- SVMH's team
 - Infectious Disease specialists
 - Pharmacy
 - Microbiology
 - Infection Prevention
 - Nursing
 - Quality Improvement
 - Informatics

Pharmacist managed antibiotic dosing and blood levels

Antibiotic	Blood level timing	Therapeutic goal mcg/mL	Toxic level mcg/mL	notes
IV Vancomycin	1 hour before next dose	10-15	>20	Levels are not indicated for Oral vancomycin formulation
Gentamicin Tobramycin	Trough-30 minutes before next dose Peak-30 minutes after end of infusion	Trough <1 Peak varies depending on indication 4-6 Up to 8-12	Trough >2	Trough for extended infusion; Peak and trough for conventional dosing
Amikacin	Trough-30 minutes before next dose Peak-30 minutes after end of infusion	Trough 1-8 Peak 20-30		

SVMH Stewardship Interventions

- Pre-authorization of restricted and broad-spectrum antibiotics
- Audit and feedback
 - ICU multidisciplinary rounds
 - House-wide antibiotic reviews with ID and pharmacy
 - Pharmacy review of cultures and sensitivity results
- Rapid testing of blood cultures that yields results within hours (Verigene)
- IV to PO conversions
- Informal and formal ID consults generated from stewardship
- Pharmacokinetic dosing and monitoring of high-risk antimicrobials

Strategies for Improved Antimicrobial Prescribing



1. Ensure antibiotics are indicated
2. Select an appropriate antibiotic with a **narrow spectrum** if possible, to minimize collateral damage
3. Ensure that antibiotic durations are evidence-based and take into account clinical response. Use the **shortest** appropriate **length of therapy**
4. Remember to **re-evaluate** therapy based on culture results, laboratory data, clinical status, etc. **De-escalate** therapy, convert IV to PO, and discontinue therapy when appropriate

Are Antibiotics Needed?

Illness	Usual Cause		Antibiotic Needed
	Viruses	Bacteria	
Cold/Runny Nose	✓		NO
Bronchitis/Chest Cold (in otherwise healthy children and adults)	✓		NO
Whooping Cough		✓	Yes
Flu	✓		NO
Strep Throat		✓	Yes
Sore Throat (except strep)	✓		NO
Fluid in the Middle Ear (otitis media with effusion)	✓		NO
Urinary Tract Infection		✓	Yes

For Clean Surgeries, Avoid Continuing Prophylactic Antibiotics after Surgical Closure

- Surgeries are generally considered “clean” if respiratory, alimentary, genital, or urinary tracts are not entered
- Examples of clean procedures that usually do not require continuing antibiotics after the procedure: orthopedic surgeries, ophthalmic surgeries, plastic surgeries, laminectomies, spinal fusions, pacemaker surgeries, etc.
- Exclusions (cases that may require post-op antibiotics)
 - Non-clean cases in which respiratory, alimentary, genital or urinary tracts are entered
 - Cardiothoracic surgeries
 - Antibiotics not used for peri-operative prophylaxis (e.g. initiated for treatment of active infections)

SVMH Antibioqram

- Includes SVMH antibiotic susceptibility information, empiric therapy recommendations, tailored therapy recommendations for Verigene results, and antibiotic stewardship clinical pearls
- Available on STARnet Pharmacy Page, in physician's lounge, or contact Microbiology Department for a copy

Follow



Pharmacy
Pharmacy Services

Following



Quick Links

Antibioqram 2018

Empiric Antibiotic Selections for Adults	
ONS	Bacterial Meningitis - Community Acquired (<i>S. pneumoniae</i> , <i>N. meningitidis</i>) Ceftriaxone IV 2 g q12hr + vancomycin IV If patient is immunocompromised or >50 years old, add ampicillin IV 2 g q6hr Post-neurosurgical (<i>Pseudomonas</i> spp., <i>S. aureus</i> , <i>S. epidermidis</i> , CNS) Vancomycin IV + ceftazidime IV 2 g q8hr. Ceftaz may be subs. w/ ceftipime or ceftazepime if ID approval
Pneumonia	Community Acquired Pneumonia (<i>S. pneumoniae</i> , <i>H. influenzae</i> , <i>M. pneumoniae</i> , <i>C. pneumoniae</i>) Usually treated for 7-8 days Non-ICU: Ceftriaxone IV 1 g q8hr + IV azithromycin 500mg day 1 followed by 250 mg PO daily x 4 or IV 500 mg daily x 3 days ICU: Consider piperacillin/tazobactam IV 3.375 g q6hr (extended infusion) + vancomycin IV HAP/VAP (<i>CAP</i> organisms, <i>P. aeruginosa</i> , <i>Enterobacter</i> spp.) Usually treated for 7 days Piperacillin/tazobactam IV 3.375 g q6hr (extended infusion) + vancomycin + aminoglycoside
Abdominal	Intra-abdominal (enteric gram-negative rods, anaerobes, enterococci, streptococci) Usually treated for 4-7 days with source control Piperacillin/tazobactam IV 3.375 g q6hr (extended infusion) Or consider Ceftriaxone IV 2 g q8hr + metronidazole IV 500 mg q6hr Consider adding anti-fungal agents in select patients (e.g. pure candida culture from abdominal cavity or blood, positive fungal biomarkers and pt. not responding to antibiotics, recurrent laparotomies, post-liver-surgery transplants, critically ill/bleeds) CDI (<i>C. difficile</i> infection) Oral vancomycin 500 mg four times daily for 10 days is 1st line for CDI treatment
Urinary Tract	Uncomplicated cystitis (<i>E. coli</i> , <i>P. mirabilis</i> , <i>K. pneumoniae</i>) Usually treated for 3-5 days Ceftriaxone IV 1 g q6hr Pyelonephritis Usually treated for 7-10 days Ceftriaxone IV 1 g q6hr
Skin & Soft Tissue	Uncomplicated cellulitis (<i>Strep-hemolytic streptococci</i> , <i>S. aureus</i>) Usually treated for 7-8 days Cefazolin IV 1 g q6hr If purulent cellulitis, treat with vancomycin IV Complicated cellulitis (polymicrobial) Usually treated for 7-10 days Ampicillin/sulbactam IV 2 g q6hr Or consider Piperacillin/tazobactam IV 3.375 g q6hr (extended infusion) + vancomycin IV

Salinas Valley
Memorial
Healthcare System

ANTIBIOGRAM

Microbiology Antimicrobial
Susceptibility Data Sheet

2018

458 East Main St
Salinas, CA 95061

Antibioqram 2018
Data is Percent Susceptible

Organism	Totals	Antibiotic																					
		AM	SAM	CE	CAZ	CRD	CC	SXT	E	SM	GMI	LVL	MR	FTM	M	PO	PVV	STI	TE	NN	T2P	VA	
ORGANISM		AM	SAM	CE	CAZ	CRD	CC	SXT	E	SM	GMI	LVL	MR	FTM	M	PO	PVV	STI	TE	NN	T2P	VA	
CITROBACTER	78			92	87	87		85	96	96	96		87										
ENTEROBACTER	140			86	86	86		93	96	96	94	20								97	82		
E. COLI	1688	54	62	79	87	87		73	88	88	76	95								87			
KLEBSIELLA	322		86	88	93	93		90	94	95	95	32								93	95		
P. MIRABILIS	177	86	92	92	94	94		74	90	76	76									95	99		
S. MARCESCENS	29			100	100			100	100	100	97									97	100		
P. AERUGINOSA	169			86						95	84									97	91		
ENTEROCOCCUS	335	94								65	77									90			96
S. AUREUS	467						80	97						67						94			100
S. AGALACTIAE	126						41	78	34						100	100							100
S. PNEUMONIAE	40				100			78	79		98												100

Genus	Species	Verigene Result Recommendations		Treatment of Choice
		Staphylococci	Streptococci	
Staphylococci	<i>S. aureus</i>	methA	MISA	Cefazolin or nafcillin
	<i>S. epidermidis</i>	methA	MISE	Vancomycin
	<i>S. pneumoniae</i> (Grp A)	methA	MISE	Possible contaminants if only one blood or positive, if not treat w/ cefaz
Streptococci	<i>S. pneumoniae</i> (Grp B)	-	-	nafcillin, cefazolin
	<i>S. agalactiae</i> (Grp B)	-	-	penicillin, ceftriaxone
Enterobacteriaceae	<i>E. coli</i> , <i>Proteus</i> spp., <i>K. pneumoniae</i>	cTX-M	eTX-M	Ceftriaxone
	<i>E. faecalis</i>	vVanA/B	VRE	Diapto or linezolid w/ ID approval
Enterococci	<i>E. faecium</i>	vVanA/B	VRE	Diapto or linezolid w/ ID approval

Antibiotic	Consider using PO instead of IV formulations for the following antibiotics:
Azithromycin (25-50% oral bioavailability)	
Clindamycin (~90% oral bioavailability)	
Doxycycline (~90% oral bioavailability)	
Fluconazole (>90% oral bioavailability)	
Levofloxacin (~99% oral bioavailability)	
Linezolid (~100% oral bioavailability)	
Metronidazole (~80% oral bioavailability)	
Rifampin (~90-95% oral bioavailability)	
Sulfamethoxazole/trimethoprim (90-100% oral bioavailability)	

Clinical Pearls

- If patient clinically improves in therapy, use the shortest recommended duration of therapy to reduce risk of c-diff and other adverse effects.
- Avoid all proton pump inhibitors during CDI management.
- In non-pregnant and non-neutropenic patients, avoid antibiotics for asymptomatic bacteriuria and low colony urine counts (< 100,000 CFU/mL). Take into account antibiotic resistance.
- Double-antenna coverage is not needed; pif/iso (Zosyn), ampic/sulbactam (Unasyn), and carbapenems have great anaerobic coverage.
- For *S. aureus* bacteremia, use IV therapy.
- Double gram-negative coverage usually not needed based on our susceptibility data. If used, de-escalate with final susceptibility result.
- Avoid quinolones unless severe CDI allergy or no alternative treatment options in uncomplicated respiratory/urinary infections.
- Avoid quinolones due to increased risks of aortic rupture, hypoplasia, and CNS effects.

Tailored Therapy Based on Verigene

- New molecular blood culture test implemented at SVMH
- Rapidly identifies gram-positive and gram-negative bacteria in a few hours
- Improved turnaround time of blood culture tests by 30-40 hours compared to standard methods
- These tests, **when acted upon in a timely manner**, have been shown to improve patient outcomes (decreased lengths of stay, cost-savings)

Verigene

- Verigene detects 12 different gram-positive and 8 gram-negative organisms as well as genetic markers for antibiotic resistance
- Differentiates methicillin-sensitive staphylococcus aureus (MSSA) from methicillin-resistant Staphylococcus aureus (MRSA) by identifying the resistance-conferring mecA gene
- Differentiates vancomycin-sensitive Enterococci from vancomycin-resistant Enterococci (VRE)
- Detects genetic resistance markers such as those associated with extended-spectrum beta-lactamases (ESBL)

Verigene Result Recommendations

Genus	Species	Resistance Markers		Treatment of Choice
Staphylococci	<i>S. aureus</i>	-mecA	MSSA	Cefazolin or nafcillin
		+mecA	MRSA	Vancomycin
	<i>S. epidermidis</i>	-mecA	MSSE	Possible contaminant if only one blood cx positive. If not, treat w/ vanco
		+mecA	MRSE	
Streptococci	<i>S. pyogenes (Grp A)</i>	-	-	Penicillin, cefazolin
	<i>S. agalactiae (Grp B)</i>	-	-	Penicillin, cefazolin
	<i>S. anginosus grp</i>	-	-	Penicillin, ampicillin, ceftriaxone
	<i>S. pneumoniae</i>	-	-	Ceftriaxone
Enterobacteriaceae	<i>E.coli, Proteus K. pneumoniae</i>	-CTX-M	-	Ceftriaxone
		+CTX-M	+ESBL	Meropenem w/ ID approval
Enterococci	<i>E. faecalis</i>	-VanA/B	-	Ampicillin
		+VanA/B	VRE	Dapto or linezolid w/ID approval
	<i>E. faecium</i>	-VanA/B	-	Ampicillin
		+VanA/B	VRE	Dapto or linezolid w/ID approval

Intravenous to Oral Therapy



Converting IV to PO maintains efficacy while

- Supporting earlier ambulation
- Decreasing complications from IV lines (thrombophlebitis, infections)
- Decreasing lengths of stay
- Decreasing equipment and drug costs
- Saving personnel time (nursing administration time, pharmacy compounding time)

IV to PO Conversions

Patients can be considered for IV to PO conversions when they are:

- Taking other oral medications
- Improving clinically (normal vital signs, hemodynamically stable, improving WBC, etc.)
- Have no conditions that might affect GI absorption of medications (e.g. persistent nausea/vomiting, ileus, active GI bleed, etc.)

Examples of IV to PO Conversions

Sequential Therapy (same agent but changing from IV to PO dosage form with the same or orally equivalent dose)

- **Azithromycin** (35-50% oral bioavailability but has excellent distribution to the lungs)
- **Clindamycin** (~90% oral bioavailability)
- **Doxycycline** (~90% oral bioavailability)
- **Famotidine** (~50% oral bioavailability)
- **Fluconazole** (>90% oral bioavailability)
- **Levofloxacin** (~99% oral bioavailability)
- **Levothyroxine** (~50% oral bioavailability)
- **Linezolid** (~100% oral bioavailability)
- **Metronidazole** (~80% oral bioavailability)
- **Pantoprazole** (~80% oral bioavailability)
- **Rifampin** (~90-95% oral bioavailability)
- **Sulfamethoxazole/trimethoprim** (90-100% oral bioavailability)

Step-Down Antimicrobial Therapy (conversion to a different agent that offers a similar spectrum of activity)

- **Ampicillin** → amoxicillin
- **Ampicillin/sulbactam** → amoxicillin/clavulanate
- **Aztreonam** → ciprofloxacin or levofloxacin
- **Cefazolin** → cephalexin
- **Cefotaxime or ceftriaxone** → cefpodoxime or cefuroxime axetil
- **Ceftazidime or cefepime** → ciprofloxacin or levofloxacin
- **Piperacillin/tazobactam** → levofloxacin + metronidazole, or levofloxacin + amoxicillin/clavulanate

Shorter Durations of Therapy

- Recent studies have shown that shorter antibiotic courses often work just as well, and may be preferred to longer courses due to a reduced risk of developing resistance and developing superinfections

INFECTIONS	DIAGNOSTIC CONSIDERATIONS	EMPIRIC THERAPY	DEFINITIVE THERAPY Tailor to culture results and define duration, including discharge prescription.
Skin and soft tissue infection	Develop diagnostic criteria to distinguish purulent and non-purulent infections and severity of illness (i.e., mild, moderate and severe) so that skin and soft tissue infections can be managed appropriately according to guidelines.	Avoid empiric use of antipseudomonal beta-lactams and/or anti-anaerobic agents unless clinically indicated. Use of therapy specific for MRSA may not be necessary in uncomplicated non-purulent cellulitis ⁽⁵³⁾ .	Guidelines suggest that most cases of uncomplicated bacterial cellulitis can be treated for 5 days if the patient has a timely clinical response ⁽⁵³⁾ .

INFECTIONS	DIAGNOSTIC CONSIDERATIONS	EMPIRIC THERAPY	DEFINITIVE THERAPY Tailor to culture results and define duration, including discharge prescription.
Community-acquired pneumonia⁽⁵⁴⁾	Review cases after initiation of therapy to confirm pneumonia diagnosis versus non-infectious etiology.	Avoid empiric use of antipseudomonal beta-lactams and/or MRSA agents unless clinically indicated.	<p>Guidelines suggest that in adults, most cases of uncomplicated pneumonia can be treated for 5 days when a patient has a timely clinical response ^(55, 56).</p> <p>Data also suggest that negative results of MRSA nasal colonization testing can help guide decisions to discontinue empiric therapy for MRSA pneumonia ⁽⁵⁷⁾</p>

INFECTIONS

DIAGNOSTIC CONSIDERATIONS

EMPIRIC THERAPY

DEFINITIVE THERAPY

Tailor to culture results and define duration, including discharge prescription.

Urinary tract infection (UTI)

Implement criteria for ordering urine cultures to ensure that positive cultures are more likely to represent infection than bladder colonization ⁽⁵⁸⁾.

Examples include:

- Order a urine culture only if the patient has signs and symptoms consistent with UTI such as urgency, frequency, dysuria, suprapubic pain, flank pain, pelvic discomfort or acute hematuria.
- For patients with urinary catheters, avoid obtaining urine cultures based solely on cloudy appearance or foul smell in the absence of signs and symptoms of UTI. Nonspecific signs and symptoms such as delirium, nausea and vomiting should be interpreted with caution as, by themselves, they have a low specificity for UTI.

Establish criteria to distinguish between asymptomatic and symptomatic bacteriuria.

Avoid antibiotic therapy for asymptomatic bacteriuria except in certain clinical situations where treatment is indicated, such as for pregnant women and those undergoing an invasive genitourinary procedure.

Use the shortest duration of antibiotic therapy that is clinically appropriate.

Reducing Clostridium Difficile Infections

- Prevention
 - Hand hygiene
 - Isolation
 - Environmental decontamination
- Improve prescribing
 - Minimize the use of excessively broad-spectrum antimicrobials when treating infections to lessen the disruption of gastrointestinal normal flora. Minimize the use of drugs commonly associated with c. diff (clindamycin, levofloxacin and other fluoroquinolones, etc.)
 - Minimize antibiotic exposures to the shortest reasonable duration
 - Avoid gastric acid suppression, such as with Proton-Pump-Inhibitors, unless clinically indicated (e.g. mechanical ventilation, coagulopathy, high dose corticosteroids, sepsis, history of GI bleed, traumatic brain, spinal cord, or burn injury, etc.)

